Trial Profile

A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXP 900 (Primary) ; Osimertinib (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Nuvectis Pharma

Most Recent Events

04 Aug 2026 According to a Nuvectis Pharma media release, Company expects updated data from this trial by the end of 2026.
31 Mar 2026 According to Nuvectis Pharma media release, the data from the trial will be presented at the upcoming 2026 American Association for Cancer Research Meeting (2026 AACR).
11 Feb 2026 According to Nuvectis Pharma media release, the company expects a data readout in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com